SK502001A3 - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions Download PDF

Info

Publication number
SK502001A3
SK502001A3 SK50-2001A SK502001A SK502001A3 SK 502001 A3 SK502001 A3 SK 502001A3 SK 502001 A SK502001 A SK 502001A SK 502001 A3 SK502001 A3 SK 502001A3
Authority
SK
Slovakia
Prior art keywords
acid
methyl
phenyl
biphenyl
hydroxy
Prior art date
Application number
SK50-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SK502001A3 publication Critical patent/SK502001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
SK50-2001A 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions SK502001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
SK502001A3 true SK502001A3 (en) 2002-06-04

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
SK50-2001A SK502001A3 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (id)
JP (1) JP2002521328A (id)
KR (1) KR20010083134A (id)
CN (1) CN1310629A (id)
AP (1) AP2001002035A0 (id)
AU (1) AU4701799A (id)
BG (1) BG105162A (id)
BR (1) BR9912296A (id)
CA (1) CA2335062A1 (id)
CZ (1) CZ2001126A3 (id)
EA (1) EA200100153A1 (id)
EE (1) EE200100046A (id)
HR (1) HRP20010055A2 (id)
HU (1) HUP0102880A3 (id)
ID (1) ID30030A (id)
IL (1) IL140982A0 (id)
IS (1) IS5809A (id)
NO (1) NO20010291L (id)
OA (1) OA11584A (id)
PL (1) PL346011A1 (id)
SK (1) SK502001A3 (id)
TR (1) TR200100205T2 (id)
WO (1) WO2000004892A2 (id)
YU (1) YU3501A (id)
ZA (1) ZA200100294B (id)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (zh) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
AU2001282541B2 (en) * 2000-09-01 2004-06-24 Sankyo Company, Limited Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
ATE399012T1 (de) * 2002-04-03 2008-07-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
JP4617449B2 (ja) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
WO2016113713A1 (en) * 2015-01-15 2016-07-21 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
NZ312571A (en) * 1995-08-04 2000-07-28 Warner Lambert Co Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein
DK0901466T3 (da) * 1996-05-17 2002-02-18 Warner Lambert Co Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer
JP2000517341A (ja) * 1996-09-04 2000-12-26 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼ阻害剤およびそれらの治療的使用

Also Published As

Publication number Publication date
OA11584A (en) 2004-07-20
BR9912296A (pt) 2001-04-17
WO2000004892A3 (en) 2000-05-18
PL346011A1 (en) 2002-01-14
AU4701799A (en) 2000-02-14
NO20010291D0 (no) 2001-01-18
CA2335062A1 (en) 2000-02-03
YU3501A (sh) 2005-06-10
IL140982A0 (en) 2002-02-10
HRP20010055A2 (en) 2002-04-30
EE200100046A (et) 2002-06-17
IS5809A (is) 2001-01-12
EP1098662A2 (en) 2001-05-16
CN1310629A (zh) 2001-08-29
CZ2001126A3 (cs) 2002-01-16
ID30030A (id) 2001-11-01
HUP0102880A2 (en) 2002-06-29
AP2001002035A0 (en) 2001-03-31
WO2000004892A2 (en) 2000-02-03
TR200100205T2 (tr) 2001-05-21
HUP0102880A3 (en) 2002-11-28
ZA200100294B (en) 2002-01-10
EA200100153A1 (ru) 2001-08-27
JP2002521328A (ja) 2002-07-16
NO20010291L (no) 2001-01-18
BG105162A (en) 2001-12-29
KR20010083134A (ko) 2001-08-31

Similar Documents

Publication Publication Date Title
AU741768B2 (en) Method for treating and preventing heart failure and ventricular dilatation
AU737117B2 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
US6133304A (en) ACE inhibitor-MMP inhibitor combinations
SK502001A3 (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
US20020049237A1 (en) Statin-MMP inhibitor combinations
KR20010041916A (ko) 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
US20050020607A1 (en) Statin-MMP inhibitor combinations
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
MXPA00003736A (en) Ace inhibitor-mmp inhibitor combinations
AU2003248291A1 (en) Statin-matrix metalloproteinase inhibitor combinations
MXPA99002254A (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing